Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.

[1]  J. Holst,et al.  Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo‐controlled, double‐blind, parallel‐group study , 2017, Diabetes, obesity & metabolism.

[2]  T. Wadden,et al.  Intensive Lifestyle Intervention for Obesity: Principles, Practices, and Results. , 2017, Gastroenterology.

[3]  Raymond L. Forbes,et al.  3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial , 2017, The Lancet.

[4]  P. Hellström,et al.  Bariatric surgery – time to replace with GLP-1? , 2017, Scandinavian journal of gastroenterology.

[5]  T. Wadden,et al.  Mechanisms, Pathophysiology, and Management of Obesity , 2017, The New England journal of medicine.

[6]  C. Mantzoros,et al.  GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial , 2016, Diabetologia.

[7]  L. Igel,et al.  Pharmacotherapy for Obesity. , 2016, Endocrinology and metabolism clinics of North America.

[8]  A. Flint,et al.  Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics , 2015, Clinical Pharmacokinetics.

[9]  A. Zinsmeister,et al.  Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study , 2015, Physiological reports.

[10]  A. Astrup,et al.  A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. , 2015, The New England journal of medicine.

[11]  T. Wadden,et al.  The Questionnaire on Eating and Weight Patterns-5: an updated screening instrument for binge eating disorder. , 2015, The International journal of eating disorders.

[12]  A. Zinsmeister,et al.  Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy. , 2015, Gastroenterology.

[13]  Alan D. Lopez,et al.  Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2014, The Lancet.

[14]  R. Oikawa,et al.  Differing effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes , 2014, Diabetes, obesity & metabolism.

[15]  M. Horowitz,et al.  Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia , 2014, Diabetes.

[16]  B. Sloth,et al.  Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults , 2013, International Journal of Obesity.

[17]  A. Pietraszek,et al.  Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat‐rich meal in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, cross‐over trial , 2013, Diabetes, obesity & metabolism.

[18]  J. Tack,et al.  Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion , 2013, International Journal of Obesity.

[19]  M. Camilleri,et al.  Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants , 2012, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[20]  C. Kapitza,et al.  Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. , 2012, Diabetes research and clinical practice.

[21]  J. Jelsing,et al.  Liraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight , 2012, Diabetes, obesity & metabolism.

[22]  J. Holst,et al.  Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans , 2011, Diabetes.

[23]  C. Kapitza,et al.  The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients , 2011, Advances in therapy.

[24]  Dennis D. Kim,et al.  The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes , 2007, Annals of Internal Medicine.

[25]  M. Camilleri,et al.  SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication , 2002, Gut.

[26]  B. Brinkmann,et al.  Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[27]  D. Kivlahan,et al.  The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. , 1998, Archives of internal medicine.

[28]  P. Rorsman,et al.  Desensitization of glucagon‐like peptide 1 receptors in insulininsulinsecreting βTC3 cells: role of PKA‐independent mechanisms , 1996 .

[29]  N. Read,et al.  The effect of incorporating fat into different components of a meal on gastric emptying and postprandial blood glucose and insulin responses , 1989, British Journal of Nutrition.

[30]  R. Snaith,et al.  The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.